IMULAN BioTherapeutics' ImSAIDs Demonstrate Promise for Pancreatitis
Canine and feline pancreatitis are disease targets for the Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) from IMULAN BioTherapeutics.
Prescott, AZ, (PRWEB) May 16, 2008 -- IMULAN BioTherapeutics, LLC (IMULAN) announced one of their lead Immune Selective Anti-Inflammatory Derivatives (ImSAIDs) has demonstrated promise for preventing and treating pancreatitis. The ImSAIDs are a new generation of anti-inflammatory and appear to block inflammation regardless of the cause, making them useful for all types of inflammation. The independent study's findings were recently published in the April issue of the AJP-Gastrointestinal and Liver Physiology.
Dr. Craig Woods, CEO of IMULAN, stated, "This is a very encouraging study which may translate into a new approach for the prevention and treatment of pancreatitis in people and animals. The study supports the versatility of the ImSAIDs, which have also been examined in models of asthma, sepsis, anaphylaxis, and neurological trauma with very promising results."
Dr. Woods went on to state, "IMULAN is considering this particular ImSAID for the treatment of canine and feline pancreatitis, which often have catastrophic consequences. This same ImSAID is also under development for feline asthma, a comparative model to human asthma. We hope the work done on the ImSAIDs will eventually translate into benefits for children and adults which suffer from pancreatitis, asthma and other diseases."
About Canine and Feline Pancreatitis: Canine pancreatitis is often a severe, life threatening emergency with no approved veterinary therapy for this condition. It affects numerous dogs each year, with certain breeds being predisposed such as miniature schnauzers. Pancreatitis is now becoming a more recognized problem in feline patients, but the underlying causes are often not known.
About the Immune Selective Anti-Inflammatory Derivatives (ImSAIDs): The ImSAIDs are potent biological derivatives of a larger protein identified from the salivary gland. Studies to date show the ImSAIDs modulate cellular activation and chemotaxis, two important events in triggering and perpetuating inflammation. To date, the ImSAIDs have demonstrated significant effects in animal models of asthma, spinal trauma, endotoxemia, allergic reactions, and anaphylaxis.
About IMULAN BioTherapeutics: IMULAN develops unique, precision immune regulating compounds for veterinary medicine. IMULAN's primary focus is on biological strategies that combine peptide pharmacology with immunology to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN recently commercialized Lymphocyte T-Cell Immunomodulator (LTCI) as a conditionally licensed treatment aid for cats infected with feline leukemia virus (FeLV) and feline immunodeficiency virus (feline AIDS or FIV).
For additional information on ImSAIDs or IMULAN, please call 877-892-9595 or visit www.IMULAN.com.
Contact:
Dr. Craig Woods, CEO
IMULAN BioTherapeutics
877.892.9595
cwoods @ imulan.com
###
|
